Jingoism buried, IPO done, stock price up 50%. What next for Gland Pharma?
Its IPO was talk of the town, but investors gave it a miss. Now, the company is having the last laugh
V Keshavdev - December 10, 2020
New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Tricky Transition
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
N Mahalakshmi - July 16, 2019
The Eclipse of A Star
Investors worry about poor corporate governance practices at Sun Pharma and price erosion in the US generics market
Prathamesh Mulye - March 25, 2019
Cherry-Picking Fallen Angels — Part 2
Here is a list of stocks that have fallen in the small and mid-cap carnage despite reporting robust numbers
Prathamesh Mulye - July 19, 2018
The Comeback Plan
Lupin is betting on its specialty drugs business to counter the pricing pressures in the US generics market
Khushboo Balani - October 03, 2017
Master Innovator
Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space
Shilpa Elizabeth Abraham - June 09, 2017
Vivek Pandey
Private portfolio manager Vivek Pandey is backing Wockhardt thanks to its long ANDA pipeline
Vivek Pandey - December 10, 2015
